Plasma free iron and chemotherapy toxicity
- 1 February 1996
- journal article
- Published by Elsevier in The Lancet
- Vol. 347 (8998), 342-343
- https://doi.org/10.1016/s0140-6736(96)90530-9
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Presence of iron catalytic for free radical reactions in patients undergoing chemotherapy: implications for therapeutic managementCancer Letters, 1995
- Doxorubicin Reduces the Iron(III) Complexes of the Hydrolysis Products of the Antioxidant Cardioprotective Agent Dexrazoxane (ICRF-187) and Produces Hydroxyl RadicalsArchives of Biochemistry and Biophysics, 1995
- New concepts of iron and aluminium chelation therapy with oral L1 (deferiprone) and other chelators. A reviewThe Analyst, 1995
- The one-ring open hydrolysis product intermediates of the cardioprotective agent ICRF-187 (dexrazoxane) displace iron from iron-anthracycline complexesInflammation Research, 1993
- Bleomycin‐reactive iron in patients with acute non‐lymphocytic leukemiaFEBS Letters, 1992
- Deferoxamine, Cyclophosphamide, Etoposide, Carboplatin, and Thiotepa (D-CECaT)American Journal of Clinical Oncology, 1992
- ICRF-187 permits longer treatment with doxorubicin in women with breast cancer.Journal of Clinical Oncology, 1992
- Entry of iron into cells: A new role for the transferrin receptor in modulating iron release from transferrinAnnals of Neurology, 1992
- Prolonged survival in patients with beta-thalassemia major treated with deferoxamineThe Journal of Pediatrics, 1991
- Mechanisms of bleomycin-induced lung damageArchives of Toxicology, 1991